Fujian Cosunter Pharmaceutical Co., Ltd.

Fujian Cosunter Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China, listed on the ChiNext board of the Shenzhen Stock Exchange since 2015. The company is dedicated to improving public health through the development of innovative solutions, particularly in the area of liver health. Cosunter focuses on the research and development of both generic and innovative drugs, employing strategies such as independent R&D, collaborative development, and mergers and acquisitions to enhance its product offerings. Cosunter's main business lines include nucleos(t)ide analogue anti-HBV drugs and hepatoprotective drugs, targeting conditions such as hepatitis B, hepatitis C, fatty liver, liver fibrosis, and liver cancer. The company also produces male health and cardiovascular drugs, with a diverse product pipeline that includes both marketed products and drugs in development. Cosunter aims to strengthen its market position by advancing its innovation-driven strategy, expanding its product range, and enhancing its global intellectual property protections. The company has established a robust sales network across China, bolstered by strong relationships with distributors and a commitment to brand building.

1. First-Mover Advantage in Innovative Drug R&D As a leading innovative drug R&D and manufacturing company in China, deeply entrenched in the antiviral and liver health sectors, the company has actively and consistently pursued an innovation-driven development strategy since its listing in 2015. It has strategically expanded into areas such as liver cancer, non-alcoholic steatohepatitis (NASH), and clinical cure for hepatitis B, aiming to fill industry gaps and actively fulfill corporate social responsibilities by initiating the development of innovative anti-COVID-19 drugs. Through years of innovative transformation and development, the company has achieved a breakthrough in innovative drugs, with its anti-COVID-19 drug Taizhongding approved for market launch and commercialization. It now possesses full-cycle R&D capabilities for innovative drug development and has established a pipeline of innovative drug products. Additionally, the company has strengthened global intellectual property protection for its innovative drugs, with PCT international patent filings for its series of innovative drug compounds, and has successively obtained patent authorizations in China and other countries or regions. By continuously increasing R&D investment and refining its intellectual property layout for innovative drugs, the company has seized a certain first-mover advantage in the innovative drug market and is gradually building its unique moat and core competitiveness. 2. Experienced Management Team Advantage The company has continuously improved the construction of its innovative drug R&D and management team, boasting a professional team that covers various stages of the drug development lifecycle and comprehensive corporate operations. Core R&D and management personnel hail from multinational corporations such as Pfizer, GSK, and AstraZeneca, bringing extensive experience in clinical research, regulatory submissions, and commercialization of innovative drugs. In the future, the company will continue to attract outstanding management and R&D talent to enhance its independent innovation capabilities and drive high-quality development. 3. Strategic Focus and Diversified Product Pipeline Advantage Through independent R&D, collaborative development, and industrial mergers and acquisitions, the company has established a drug matrix that focuses on nucleos(t)ide anti-HBV drugs and liver-protecting drugs, with comprehensive coverage of liver health product lines including hepatitis B, hepatitis C, fatty liver disease, liver cancer, and liver protection. This is complemented by products in areas such as anti-COVID-19, cardiovascular health, and men’s health. In the future, with the anticipated approval and market launch of high-end generic drugs such as Clopidogrel Bisulfate and Aspirin Tablets, as well as the successive entry of multiple innovative drug R&D products into the harvest phase, the company’s product pipeline will be further enriched and upgraded, enhancing long-term development momentum. 4. Brand and Channel Advantage With years of dedication to the anti-hepatitis B virus drug sector, the company has established a sales force spanning all provinces in China and a sales network covering capitals, cities, and counties nationwide. It has also built solid cooperative relationships with outstanding distributors in this field. Through years of academic promotion and brand building, the company has earned a reputation among doctors and patients in this sector, establishing a strong brand image that lays the foundation for future revenue growth and the market introduction of new products. Simultaneously, the company adapts to industry changes by continuously exploring diversified sales channels, actively investigating new retail models in healthcare, expanding new retail channels (such as online pharmacies and internet hospitals), and implementing digital marketing practices to empower channel construction. 5. Supply Chain and Quality Control Advantage The company always prioritizes the stability and improvement of product quality as a key objective in its daily operations. It continuously strengthens its quality culture through comprehensive training on products, regulations, quality tools, and management capabilities to enhance overall emphasis on product quality standards. In accordance with the "Drug Administration Law of the People’s Republic of China" and the "Good Manufacturing Practice (GMP)" regulations, the company has established a stringent product production quality assurance system. From the sourcing and production of raw materials to product manufacturing, R&D management, and clinical research, all processes adhere to GMP quality control standards. Through the control of key indicators, the company ensures the continuous and stable operation of its quality management system.